

Montana Healthcare Programs Drug Utilization Review Board Agenda
Hosted by Mountain Pacific Quality Health

September 17, 2025

1-5 PM

Virtual Call Only

Register in advance for this meeting:

<https://events.teams.microsoft.com/event/00ce34a5-f2d8-4b55-ad85-c09a5acf02dd@1f053f7a-e47d-43fd-9182-8507c9ff10c7>

1. Introductions

2. Public Comment- 15 minutes

Public Comment will be permitted on items over which the DUR Board has jurisdiction. All persons wishing to speak through the video conferencing platform must notify the Department by submitting their name and topic they wish to speak on via

<https://forms.office.com/g/EkPyKbJYTv> by **noon** the day prior to the meeting. Individual comment will be limited to a maximum of 3 minutes per person and is subject to further limitations depending on the number of speakers (15 minutes divided by total speakers).

Due to time constraints, all persons are encouraged to provide written comment, especially those providing clinical information, to allow the board adequate time to review and research. Please email written comments and/or clinical information, with a statement indicating that it is public comment, to PDL@mt.gov at least 7 days prior to the meeting. Please limit clinical information to 2 pages and to new information since last review. New peer-reviewed randomized comparative controlled trials or randomized controlled trials with true health outcomes are most helpful. Please do not provide any pricing information. Materials submitted less than 7 days prior to the meeting, in excess of 2 pages, and/or including pricing information will not be included in the board members' meeting packets.

3. Meeting Minutes

- June DUR Board

4. Department Update

5. PA Criteria Update

- Criteria Changes/Dosing & Age Updates
 - Doptelet® age expansion
 - Otezla® age expansion

- New Indication/Formulation
 - Dupixent® new indication
 - Kerendia® new indication
 - Motpoly XR® new indication
 - Nucala® new indication
 - Zoryve® new indication

6. New Drugs

- Anzupgo® topical cream
- HAE new drugs (Andembry®, Dawnzera®, and Ekterly®) and guideline expansion and criteria update
- Vykat XR®
- Yutrepia®

7. Criteria Discussion

- CGRP review for migraine

8. PA Criteria removal or changes

- Clobazam